ALNAIR THERAPEUTICS
Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult-to-treat malignancies. It has created a first-of-its-kind drug delivery technology that uses the unique features of cancer metabolism to improve drug targeting and penetration directly into cancer cells, hence enhancing patient treatment outcomes.
ALNAIR THERAPEUTICS
Social Links:
Industry:
Biotechnology Oncology
Total Employee:
1+
Status:
Active
Total Funding:
1.76 M USD
Similar Organizations
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Fore Biotherapeutics
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Investors List
OCA Ventures
OCA Ventures investment in Pre Seed Round - Alnair Therapeutics
Gaingels
Gaingels investment in Pre Seed Round - Alnair Therapeutics
CJM Ventures
CJM Ventures investment in Pre Seed Round - Alnair Therapeutics
Portal Innovations
Portal Innovations investment in Pre Seed Round - Alnair Therapeutics
University of Chicago New Venture Challenge
University of Chicago New Venture Challenge investment in Grant - Alnair Therapeutics
George Shultz Innovation Fund
George Shultz Innovation Fund investment in Grant - Alnair Therapeutics
More informations about "Alnair Therapeutics"
Alnair Therapeutics Company Profile 2024: Valuation, …
Alnair Therapeutics General Information Description. Operator of a precision oncology company designed to focus on new methods to treat difficult-to-treat cancers. The company offers first-in-class drug delivery technology that …See details»
Alnair Therapeutics - LinkedIn
Alnair Therapeutics | 221 followers on LinkedIn. We are building game changing cancer therapies via previously undruggable targets | Alnair is a preclinical stage, platform precision oncology ...See details»
Alnair Therapeutics - Funding, Financials, Valuation & Investors
Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult. Search Crunchbase. ... How much funding has this …See details»
Alnair Therapeutics - Products, Competitors, Financials, Employees ...
Jul 4, 2023 Alnair Therapeutics Awarded $175,000 From George Shultz Innovation Fund Published on Monday, January 30, 2023 Xiaoyang Wu is an associate professor in the Ben …See details»
Alnair Therapeutics Awarded $175,000 From George Shultz …
Jan 30, 2023 Alnair Therapeutics joins Riptide Therapeutics as the Fall 2022 GSIF cohort winners. Both will receive a $175,000 investment from the Fund. Both will receive a $175,000 …See details»
Alnair Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Alnair Therapeutics Inc. of Chicago, IL. Get the latest business insights from Dun & Bradstreet.See details»
Alnair Therapeutics Inc · University of Chicago
ALNAIR THERAPEUTICS INC is an entity in Chicago, Illinois registered with the System for Award Management (SAM) of U.S. General Services Administration (GSA). The entity was …See details»
Alnair Therapeutics - Crunchbase
Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult.See details»
Alnair Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse
Last update 01 Oct 2024. Alnair Therapeutics. Private Company |See details»
Alnair Therapeutics Information
Alnair Therapeutics Information Alnair is a preclinical stage, platform precision oncology company focused on new methods to treat difficult-to-treat cancers. We developed a first-in-class drug …See details»
Alnair Therapeutics Follows Polsky Path to String of Impressive …
Jul 5, 2023 Momentum continues to build for Alnair Therapeutics, an oncology startup focused on developing a platform to better deliver drugs to hard-to-treat cancers. In June – the same …See details»
2 Startups Awarded $175,000 Each to Further Develop Cancer …
Jan 30, 2023 Alnair Therapeutics and Riptide Therapeutics have been awarded investments from the George Shultz Innovation Fund to further develop their cancer treatment …See details»
Alnair Therapeutics - Raised $1M Funding from 3 investors - Tracxn
Nov 19, 2024 Alnair Therapeutics has raised a total funding of $1M over 1 round from 3 investors. Investors include OCA Ventures, Portal Innovations and 1 other. Their latest funding …See details»
MBA Ventures: More Than $1.75M In Prize Money Awarded At 2 …
Jun 12, 2023 Alnair Therapeutics wins $585,000 at the 27th Annual Edward L. Kaplan, ’71, New Venture Challenge on June 1. Photo by Anne Ryan From Chicago: Alnair Therapeutics, a …See details»
Alnair Therapeutics - Updates, News, Events, Signals & Triggers
Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult. Search Crunchbase. Start Free Trial . Chrome …See details»
Cancer-Fighting Startup Takes Top Prize at University of Chicago’s …
Out of the finals of the 2023 Edward L. Kaplan, ’71, New Venture Challenge (NVC), Alnair Therapeutics, a company with the mission to fight cancer, claimed the top spot. Launched in …See details»
Alnair Therapeutics Awarded $175,000 From George Shultz …
Alnair Therapeutics joins Riptide Therapeutics as the Fall 2022 GSIF cohort winners. Both will receive a $175,000 investment from the Fund. During the GSIF process, teams received …See details»
Oncology startup takes first place at 2023 New Venture Challenge
Jun 2, 2023 Alnair Therapeutics, a startup developing a platform technology to improve the delivery of drugs to difficult-to-treat cancers, has won first place in the 27th Annual Edward L. …See details»
Oncology Startup Takes Home First Place at 2023 NVC as Judges …
Jun 2, 2023 Alnair Therapeutics, a startup developing a platform technology to improve the delivery of drugs to difficult-to-treat cancers, has won first place in the 27th Annual Edward L. …See details»